Tetra Bio Pharma Inc TBPMQ

Healthcare Cannabis

Tetra Bio-Pharma Inc. is a Canada-based cannabinoid-derived drug discovery and development company. The Company has developed a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. The Company has a pipeline of formulations and drug delivery systems with a portfolio of assets from the early research and development phase to advanced stage clinical programs. Its products include QIXLEEF, CAUMZ, PPP004, REDUVO, and REBORN 1. QIXLEEF is a botanical therapy with a fixed dosage of tetrahydrocannabinol (THC) and cannabidiol (CBD). CAUMZ is its inhaled cannabinoid-derived drug candidate. PPP004 is a topical preparation containing either a standardized amount of CBD or a defined ratio of THC and CBD. REDUVO is a soft gel capsule used to treat chemotherapy-induced nausea and vomiting (CINV) and weight loss and severe nausea in people living with human immunodeficiency virus (HIV) infection. REBORN 1 is in phase II trial.

GREY:TBPMQ - Post by User

Tetra Bio Pharma Inc > Second choice now I guess .Not the first ?, not the only ?

<< Previous

Bullboard Posts

Next >>

Comment by SamV21on Oct 25, 2021 10:30am

62 Views

Post# 34044528

RE:Second choice now I guess .Not the first ?, not the only ?

Right out of Tetras play book from September 2020

In the current context of cannabis legalization and significant shortages of nabilone, a drug used for chemotherapy-induced nausea and vomiting, our goal is to relaunch a high value therapeutic option with robust data.

Under the terms of the agreement, TBP has agreed to acquire Dronabinol Soft Gel capsules commercial rights for two undisclosed milestones, 50% at the approval of the transaction and the other 50% once the DIN is granted by Health Canada.I guess that is why they can not give net numbers on income from it , undisclosed expences.

Dronabinol Soft Gel capsules are indicated in AIDS-related anorexia associated with weight loss and severe nausea and vomiting associated with cancer chemotherapy. Dronabinol DIN launch is expected in the first-half of 2021............We are now the the 4th Quarter of 2021 .
How are those milestones coming along ?

and you wonder why the price keeps going down, we have not seen the end of the drop in share price yet not by a long shot.
More fluff discussions , mean nothing , what is he going to say, you believe the garbage I'm sticking with results and the facts.Qixleef is light years away from being anything and Syqe has a product who Teva and Tilray are working on that is Health Canada approved already.Teva also manufactures Nabilone which is used for cancer pain already.No wonder the CFO quit , wasting shareholders money all day , everyday.